HC Wainwright & Co. Reiterates Buy on Lexicon Pharmaceuticals, Maintains $10 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for Lexicon Pharmaceuticals, maintaining a price target of $10. Analyst Joseph Pantginis continues to support the stock, indicating confidence in its potential growth.
September 11, 2024 | 10:13 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Lexicon Pharmaceuticals, maintaining a price target of $10. Analyst Joseph Pantginis continues to support the stock, indicating confidence in its potential growth.
The reiteration of a Buy rating and maintenance of a $10 price target by a reputable analyst suggests positive sentiment and potential upside for Lexicon Pharmaceuticals. This could lead to increased investor interest and a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100